Every 424B that PMV Pharmaceuticals, Inc (PMVP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PMVP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMVP filings page.
PMV Pharmaceuticals, Inc. (PMVP) is conducting a primary offering of 22,055,000 shares of common stock and pre-funded warrants for 19,900,000 shares, each sold with a common stock warrant, for total gross proceeds of $50.8 million at approximately $1.21 per unit. The offering also registers 41,955,000 common stock warrants, immediately exercisable for five years at an initial exercise price of $1.21 per share, with price and share-count adjustments tied to FDA acceptance of an NDA for rezatapopt.
PMV estimates net proceeds of about $47.0 million after fees and expenses, on top of $79.4 million in cash and equivalents as of June 30, 2026, and expects this liquidity to fund operations into the first quarter of 2028. Proceeds are earmarked primarily for late-stage development, regulatory submission and commercialization preparation for lead candidate rezatapopt in TP53 Y220C–mutant ovarian cancer.
PMV Pharmaceuticals, Inc. (PMVP) is updating its previously filed at-the-market equity program. The company had registered the offer and sale of its common stock under an Open Market Sale Agreement with Jefferies LLC, permitting issuances of shares with an aggregate offering price of up to $113,792,846.40 from time to time. This supplement terminates the company’s continuous offering under that ATM prospectus supplement, and PMV Pharmaceuticals states that no shares of common stock were sold under the program. The termination does not otherwise change the underlying sales agreement or the parties’ rights and obligations under it.
PMV Pharmaceuticals, Inc. (PMVP) is conducting a takedown under its Form S-3 shelf to offer common stock, pre-funded warrants and accompanying common stock warrants. Each share or pre-funded warrant is sold together with a common stock warrant, and this supplement also covers the shares issuable on exercise of those warrants.
The common stock warrants are immediately exercisable, expire in 2031 and have an exercise price that can reset downward after an FDA decision to accept PMV’s planned New Drug Application for rezatapopt in TP53 Y220C platinum‑resistant/refractory ovarian cancer, with a corresponding increase in warrant share count to keep the aggregate exercise price constant. Under certain positive NDA‑acceptance outcomes, PMV may require holders to exercise up to 50% of their warrants for cash, with unexercised portions lapsing.
PMV plans to seek accelerated approval for rezatapopt and expects to submit an NDA in the first quarter of 2027. Net proceeds, together with existing cash, will fund late‑stage development, regulatory submission and commercialization preparation for rezatapopt, plus working capital and general corporate purposes. As of June 30, 2026, PMV had cash, cash equivalents and restricted cash of $79.4 million, net tangible book value of $71.5 million, or $1.34 per share based on 53,460,432 shares outstanding, while the last reported Nasdaq Global Select Market sale price on August 28, 2026 was $1.22 per share.